INTRODUCTION
Methotrexate (MTX)l is a cell cycle phase-specific agent that only causes cytotoxic damage to cells when they are in S phase (1) . The number of cells killed and toxicity are exponential functions of both MTX concentration and duration of exposure (2) (3) (4) (5) . This suggests that the optimal dose schedule for cell cycle phasespecific agents such as MTX would involve high concentration exposures of sufficient duration to allow a significant proportion of tumor cells to enter S phase and be damaged (6) . This principle is firmly established for cytosine arabinoside, whose therapeutic ratio against acute leukemia increases with duration of infusion (7) . The general application of this principle is limited by the fact that most human tumors proliferate much more slowly than normal marrow and gut cells (8) (9) (10) , and in the case of MTX, bone marrow exposure must be limited to 36-40 h to avoid serious myelosuppression (11, 12) .
Under certain circumstances differential exposure of normal and malignant tissues can be achieved when the malignant cells are confined to an extravascular fluid or body cavity. The most common example of this is the successful treatment of meningeal leukemia with intrathecal MTX (13) (14) (15) . Pharmacologic modelling (16) suggested that the clearance of MTX from the peritoneal cavity would also be sufficiently less than total body clearance to allow significant differential exposure for tumor cells in the peritoneal cavity, and recent studies of MTX administered via peritoneal dialysis confirmed that at steady state the peritoneal concentration of MTX was 10-to 30-fold higher than in plasma (17) . However, at peritoneal MTX concentrations high enough to guarantee good drug penetration, enough MTX leaked into the systemic circulation to be toxic to marrow, and the duration of peritoneal dialysis had to be limited to 48 h.
MTX and reduced folate compete with each other for transport across cell membranes to gain access to both normal and malignant cells (18, 19) , and the ability of reduced folate to protect or rescue cells from MTX is dependent on the concentration ratio of the two compounds (20) (21) (22) . In the presence of high concentrations of MTX, reduced folate is unable to block the cytotoxic effect of MTX, and this has been documented in both murine tumor systems (22) (23) (24) and in man (25) . We have exploited this competitive relationship between MTX and reduced folate, and the ability of intracavitary infusion to maintain high concentrations of MTX in third spaces, to expose malignant cells confined to third spaces to a MTXlreduced folate ratio high enough to permit cytotoxicity while the normal tissues of the body were exposed to a ratio low enough to permit the reduced folate to block MTX toxicity. By simultaneously infusing MTX directly into the third space and leucovorin (5-formyltetrahydrofolate, 5fTHF) intravenously we were able to achieve tumor exposures of up to 120 h without significant bone marrow or gastrointestinal toxicity. METHODS Subjects and treatment. 18 patients with a histopathologically proven diagnoses of cancer and free flowing malignant effusions (12 pleural, 2 peritoneal, 2 pericardial) gave their written informed consent to enter this phase 1 trial. The tumor types included six bronchogenic lung, five breast, two ovarian, two melanomas, one pancreas, and one carcinoma of unknown primary. Entrance criteria included a creatinine clearance of>60 ml/min, leukocyte count (WBC) > 3,000/mm2, platelet count > 100,000/mm3, and Karnofsky status > 40%. All effusions were demonstrated to be free flowing by X-ray or ultrasound examination before treatment. Patient ages ranged from with a median of61 yr, and the median Kamofsky performance status was 50%.
Treatment was initiated by placing two plastic catheters through the body wall into the effusion at different points (one catheter was used on the two patients with pericardial effusions). MTX 30 mg/M2 per d was administered as a constant infusion at 10 mlIh through one catheter, samples were obtained for determination of MTX concentration through the other. In the case of the two pericardial effusions, the MTX infusion was periodically interrupted for sampling. Concurrent with the start of MTX infusion, leucovorin 15 mg/M2 was injected as an intravenous bolus, and leucovorin was continued at a dose rate of 10 mg/M2 i.v. every 4 h for the duration ofthe MTX infusion, and then decreased to 10 mg/M2 i.v. every 6 h until the serum MTX concentration was <50 nM. No attempt was made to quantitate the volume of the effusions because of the difficulty of obtaining accurate results and because knowledge of the volume was not essential to determination of clearance. Fluids were administered to maintain urine output at > 2 liters/d, but urinary alkalinization was not used. Each patient received only one course oftreatment, and infusion duration was escalated from 6 to 24 h, and then in 24 h increments to 120 h in subsequent patients. At the end of the MTX infusion, the effusion was drained as completely as possible and the catheters were removed. All patients who received any MTX were considered evaluable for toxicity, but only patients who survived for more than 1 mo after treatment were considered evaluable for response. Response was defined as disappearance of the effusion, and the characteristics of each response are outlined in Table IV. Drugs and drug assays. MTX and leucovorin were obtained from the Division of Cancer Treatment, National Cancer Institute. MTX concentrations were determined by radioimmunoassay using a kit generously provided by Diagnostic Biochemistry, Inc. (San Diego, Calif.). Serum reduced folate was measured with a microbiologic assay as described elsewhere (26) . Drug concentrations were averaged using the geometric mean rather than the arithmetic mean, both to reduce the variance of the data, and because biologic responses to MTX and reduced folates are log normally rather and normally distributed.
Cytokinetic measurements. Bone marrow samples were obtained from the posterior iliac crest before treatment and again at the end ofthe MTX infusion. Patients receiving 120-h infusions also had samples taken at 72 h. All samples were anticoagulated with EDTA. The activity of thymidylate synthetase was determined by measuring the rate ofincorporation of tritiated deoxyuridine ([3H]dUrd) into acid insoluble material in one part of the undiluted sample as described elsewhere (25) . Another part ofeach sample was subjected to FicollHypaque separation, and the recovered mononuclear cells were fixed, stained, and analyzed on a Phywe ICP 22 flow cytometer (Ortho Instruments, Westwood, Mass.) as described (27) . Chicken cells were added as an internal standard (28, 29) , and the proportion of cells in each phase of the cell cycle was determined by using the approximation method of Holley and Kiernan (30) . The rate of [3H]dUrd incorporation into cells in the malignant effusions was measured by the same technique (25) reasoned from the data in Fig. 1 
Pharmacokinetics. Table II shows the clearances (PA) of MTX from the effusions calculated from Eq. 4 for the condition where MTX was 50% bound. The values of PA for each type of effusion were calculated using the actual MTX concentrations in each patient rather than the geometric mean values for the whole group. In keeping with their relative membrane surfaces, clearance was smallest for the pericardial effusions (0.14 ml/min per m2), intermediate for the pleural effusions (2.6 ml/min per m2), and largest for the peritoneal effusions (6.6 ml/min per Table IV . Three of these patients received no other therapy after their MTX infusion and are thus fully evaluable: one effusion due to bronchogenic carcinoma resolved completely except for minimal blunting of the costophrenic angle, and did not recur before death at 13 mo; another due to bronchogenic carcinoma resolved completely and has not reaccumulated for 20+ mo; a peritoneal effusion due to ovarian carcinoma resolved to the point where it could not be detected by physical examination and remained controlled for 10 mo after which it reappeared. Five patients received The leucovorin dose rate, selected on the basis of pharmacokinetic parameters reported for leucovorin (26) , clearly provided enough protection to allow an otherwise lethal concentration of MTX to be maintained in the systemic circulation for up to 120 h. The general lack of clinical toxicity was accurately reflected by marrow cytokinetic measurements. Whereas a 46% decrease in incorporation of [3H]dUrd into marrow cells did occur, this degree of thymidylate synthetase inhibition was not sufficient to block cell cycle progression as evidenced by the absence of accumulation of cells at the G1/S interface that is characteristic of the MTX effect on marrow in vivo (25) .
A major concern with the use of simultaneous MTX and leucovorin is the possibility that, when concentrations of reduced folate just sufficient to protect normal tissues are present in the blood, enough reduced folate will enter the effusion to reduce the toxicity of MTX to the malignant cells. However, pharmacologic considerations argue strongly against this possibility. A concentration of leucovorin that afforded 50% protection of human marrow exposed to 1 uM MTX provided essentially no protection against a 10-fold higher concentration of MTX. These studies, whose results are in agreement with those of Bertino (39) , were done with relatively short MTX exposures and measured only inhibition of [3H]dUrd incorporation. However, leucovorin/MTX ratios of 100:1 were required to protect other sensitive cells in assays that measure proliferative ability (20) (21) (22) 40 (41) , megakaryocytes were the most sensitive to long exposures to MTX, and that in this study thrombocytopenia was the dose-limiting toxicity. There were no episodes of bacterial infection that could be attributed to the catheters. This may in part be due to the antibacterial action of MTX itself, but larger numbers of patients are needed before the risk of bacterial infection can be adequately evaluated.
The MTX clearance was greatest for the peritoneal cavity and average clearances from the pleural and pericardial cavities were only 39 and 2% of the peritoneal clearance, respectively. The average peritoneal clearance of 6.6 ml/min per m2 is close to the 8 ml/min predicted by pharmacologic modelling (16) . To our knowledge there are no previous reports ofthe clearance of MTX from the pleural or pericardial cavities.
Other investigators (17, 36, 38) have used large volume drug containing dialyses to avoid the possibility of limited diffusion of drug in the peritoneal cavity. Although with the constant infusion of MTX in small volumes, a concentration gradient between the catheter tip and the periphery of the peritoneal cavity is to be expected even at steady-state, the concentrations of MTX at the tip of the sampling catheter were well above the cytotoxic range, and the long duration of MTX infusion achieved in these patients should favor adequate although not uniform drug distribution. In the case of pleural and pericardial infusions, there is less concern about distribution of drug within the free-flowing fluid volume because the mechanical action of the lungs and the heart would be expected to result in rapid drug mixing.
Intracavitary drug delivery is likely to provide useful exposure only for small tumor masses and tumor actually on the serosal surfaces due to limited drug penetration. The tumor for which this kind oftreatment program may have the greatest impact is ovarian carcinoma. Although MTX is not the most effective drug against ovarian carcinoma, the principle of concurrent intracavitary infusion of a cytotoxic drug and systemic administration of a protective agent can now be extended to 5-fluorouracil, for which allopurinol provides concentration-dependent protection (42) (43) (44) , and cisplatinum for which sodium thiosulfate provides concentration-dependent neutralization (45 
